Want to see HK:6609 full AI Analyst Report?
Top Page
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
(6609)
Select Model
Select Model
Rating:70Outperform
Price Target:
HK$58.00
▲(6.23% Upside)
Action:Upgraded
Date:07/23/26
Overall score is driven primarily by improving fundamentals: a notable 2025 turnaround to profitability and positive free cash flow alongside a low-leverage balance sheet. The score is held back by the need to prove sustainability after recent losses and volatile cash flows, plus mixed technical momentum (negative MACD and price still below longer-term moving averages). Valuation appears reasonable but not distinctly cheap at ~18.3x earnings, with no dividend yield support provided.
Positive Factors
Revenue Scale and Growth
The substantial expansion in revenue indicates stronger product adoption and commercial scale. If maintained, a larger operating base can support investment in medical-device development, broaden market reach, and improve fixed-cost absorption.
Negative Factors
Unproven Profitability Durability
The latest profit improvement is encouraging but has not yet been demonstrated across multiple reporting periods. Continued earnings execution is needed to establish that margins reflect durable demand and operating efficiency rather than a one-period recovery.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Scale and Growth
The substantial expansion in revenue indicates stronger product adoption and commercial scale. If maintained, a larger operating base can support investment in medical-device development, broaden market reach, and improve fixed-cost absorption.
Read all positive factors
Shanghai Heartcare Medical Technology Corp. Ltd. Class H (6609) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$1.88B
Dividend YieldN/A
Average Volume (3M)31.09K
Price to Earnings (P/E)16.4
Beta (1Y)1.45
Revenue Growth59.30%
EPS Growth131.03%
CountryHK
Employees368
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)2.48
Shares Outstanding31,565,804
10 Day Avg. Volume28,950
30 Day Avg. Volume31,086
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)1.61
Price to Sales (P/S)4.47
P/FCF Ratio13.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.91
Revenue Forecast (FY)HK$546.64M
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Business Overview & Revenue Model
Company Description
Shanghai HeartCare Medical Technology Corporation Limited is a global enterprise specializing in the research, development, manufacturing, and commercialization of neuro-interventional medical devices. Its extensive product range encompasses devic...
How the Company Makes Money
null...
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
84
Very Positive
Cash Flow
78
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 513.79M | 408.29M | 277.90M | 232.34M | 183.03M | 90.09M |
| Gross Profit | 353.55M | 272.17M | 181.72M | 151.79M | 124.33M | 54.95M |
| EBITDA | 109.02M | 64.43M | 21.87M | -68.50M | -167.31M | -183.34M |
| Net Income | 92.76M | 83.33M | -13.62M | -94.01M | -200.38M | -194.22M |
Balance Sheet | ||||||
| Total Assets | 1.37B | 1.29B | 1.21B | 1.20B | 1.31B | 1.50B |
| Cash, Cash Equivalents and Short-Term Investments | 789.70M | 786.81M | 713.72M | 721.14M | 870.12M | 1.22B |
| Total Debt | 41.22M | 42.74M | 35.75M | 36.38M | 50.69M | 41.94M |
| Total Liabilities | 152.73M | 133.50M | 144.00M | 125.60M | 147.08M | 132.10M |
| Stockholders Equity | 1.22B | 1.13B | 1.06B | 1.08B | 1.17B | 1.37B |
Cash Flow | ||||||
| Free Cash Flow | 96.94M | 139.98M | -8.39M | -137.72M | -304.01M | -260.33M |
| Operating Cash Flow | 100.50M | 154.14M | -3.23M | -88.41M | -266.77M | -205.85M |
| Investing Cash Flow | -52.42M | -253.09M | 10.80M | -125.45M | 44.84M | -161.10M |
| Financing Cash Flow | -40.27M | -44.73M | -12.38M | -21.48M | -24.75M | 821.25M |
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Technical Analysis
Neutral
54.60
Price Trends
47.27
Positive
47.73
Positive
48.69
Negative
Market Momentum
-0.04
Positive
49.35
Neutral
65.41
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6609, the sentiment is Neutral. The current price of 54.6 is above the 20-day moving average (MA) of 49.36, above the 50-day MA of 47.27, and above the 200-day MA of 48.69, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 49.35 is Neutral, neither overbought nor oversold. The STOCH value of 65.41 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:6609.
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | HK$1.88B | 16.35 | 7.90% | ― | 59.30% | 131.03% | |
59 Neutral | HK$5.83B | 92.38 | 1.72% | ― | 0.75% | -20.22% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$1.63B | -0.86 | -6.69% | ― | ― | ― | |
48 Neutral | HK$3.23B | -19.27 | -7.65% | ― | 21.23% | 36.89% | |
45 Neutral | HK$11.65B | 31.24 | 6.07% | 0.06% | -3.62% | ― | |
45 Neutral | HK$515.98M | -0.99 | -28.24% | ― | -38.15% | 25.70% |
* Healthcare Sector Average
HK:6609
Shanghai Heartcare Medical Technology Corp. Ltd. Class H
47.50
-19.10
-28.68%
HK:0853
MicroPort Scientific
6.08
-7.74
-56.01%
HK:9996
Peijia Medical Ltd.
4.77
-2.53
-34.66%
HK:1302
LifeTech Scientific Corporation
1.39
-0.47
-25.14%
HK:2160
MicroPort CardioFlow Medtech Corp.
1.28
-5.97
-82.34%
HK:2500
Venus Medtech (Hangzhou), Inc. Class H
1.23
-2.61
-68.10%
Shanghai Heartcare Medical Technology Corp. Ltd. Class H Corporate Events
Shanghai HeartCare Sets August Board Meeting to Review Interim Results and Dividend
Aug 19, 2026
Shanghai HeartCare Medical Technology Corporation Limited has scheduled a board meeting for August 31, 2026 to review and approve the interim results for the six months ended June 30, 2026 for the company and its subsidiaries. The board will also ...
Shanghai HeartCare Plans A Share Issue and Sci-Tech Board Listing
Aug 14, 2026
Shanghai HeartCare Medical Technology Corporation Limited plans to issue up to 7,025,592 A shares and seek a listing on the Sci-Tech Board of the Shanghai Stock Exchange, subject to shareholder approval at an extraordinary general meeting and clea...
Shanghai HeartCare Seeks Shareholder Approval for Sci-Tech Board A-Share Issuance
Aug 14, 2026
Shanghai HeartCare Medical Technology Corporation Limited is a PRC-based medical technology company specializing in cardiovascular solutions, with existing H-share listing in Hong Kong and plans to broaden its investor base. The group aims to leve...
Shanghai HeartCare Signals Strong Interim Profit and Revenue Surge
Jul 21, 2026
Shanghai HeartCare Medical Technology Corporation Limited expects a sharp improvement in interim performance for the six months ended June 30, 2026, with revenue projected at no less than RMB280.0 million, up at least 50.9% year-on-year, and net p...
Shanghai HeartCare Raises HK$45 Million Through Targeted Domestic Share Issue
Jun 29, 2026
Shanghai HeartCare Medical Technology Corporation Limited has completed the issuance of 1,000,000 domestic shares under a specific mandate at HK$45.00 per share, increasing its total issued share capital to 38,862,008 shares, excluding treasury st...
Shanghai HeartCare Launches HKD100 Million H-Share Buyback Plan
Jun 29, 2026
Shanghai HeartCare Medical Technology Corporation Limited, a Hong Kong-listed medical technology company specializing in cardiovascular solutions, operates within the medical devices and healthcare technology sector and serves hospital and clinica...
Shanghai HeartCare Eases Grant Rules in 2025 H Share Incentive Scheme
Jun 29, 2026
Shanghai HeartCare Medical Technology Corporation Limited has amended its 2025 H Share Incentive Scheme, chiefly by revising the vesting schedule and grant timing for its 1-year and 3-year share awards. Instead of restricting grants to specific ca...
Shanghai HeartCare Completes Capital Increase and Updates Articles After Share Issuance
Jun 11, 2026
Shanghai HeartCare Medical Technology Corporation Limited has completed an issuance of new domestic shares under a specific mandate, fully paid by investors, increasing its registered capital from RMB38,834,408 to RMB39,834,408. The company has fi...
Shanghai HeartCare Announces Board Change and Audit Committee Reshuffle
Jun 10, 2026
Shanghai HeartCare Medical Technology Corporation Limited announced that non-executive director Ding Kui has resigned from the board, the audit committee and the strategy committee effective 10 June 2026 due to personal commitments. The company sa...
Shanghai HeartCare Clarifies Board and Committee Structure
Jun 10, 2026
Shanghai HeartCare Medical Technology Corporation Limited has announced the current composition of its board of directors, detailing the roles of its executive, non-executive and independent non-executive members. The board is chaired by executive...
Shanghai HeartCare wins full shareholder backing at 2025 AGM
May 28, 2026
Shanghai HeartCare Medical Technology Corporation Limited held its 2025 annual general meeting on May 28, 2026, in Shanghai, with the meeting convened in compliance with PRC company law and the firm’s articles of association. The board, led ...
Shanghai HeartCare Wins CSRC Nod for New Domestic Share Issue
May 21, 2026
Shanghai HeartCare Medical Technology Corporation Limited has obtained approval from the China Securities Regulatory Commission to register the issuance of new domestic shares to a specific subscriber under a previously granted specific mandate. T...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.